公开(公告)号：EP3393504A1

公开(公告)日：2018-10-31

申请号：EP16825970.3

申请日：2016-12-21

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania ,  Dana-Farber Cancer Institute, Inc. ,  President and Fellows of Harvard College

发明人： BROGDON, Jennifer ,  CHANG, Hwai, Wen ,  ENGELS, Boris ,  FREEMAN, Gordon, James ,  FREY, Gerhard, Johann ,  MATARAZA, Jennifer, Marie ,  SINGH, Reshma ,  SHARPE, Arlene, Helen

IPC分类号： A61K39/00

CPC分类号： A61K39/0011 ,  A61K2039/505 ,  A61K2039/5158 ,  A61K2039/545

摘要： Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

公开(公告)号：EP4245376A3

公开(公告)日：2023-12-13

申请号：EP23169814.3

申请日：2015-10-13

申请人： Novartis AG ,  Dana-Farber Cancer Institute, Inc. ,  President and Fellows of Harvard College

发明人： FREEMAN, Gordon, James ,  SHARPE, Arlene, Helen ,  FREY, Gerhard, Johann ,  CHANG, Hwai, Wen ,  MATARAZA, Jennifer, Marie ,  DRANOFF, Glenn

IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K16/46 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P35/02 ,  C07K16/30

摘要： Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

公开(公告)号：EP4378957A3

公开(公告)日：2024-08-07

申请号：EP24154217.4

申请日：2016-07-28

申请人： Novartis AG ,  Dana-Farber Cancer Institute, Inc. ,  President And Fellows Of Harvard College

发明人： DRANOFF, Glenn ,  FREEMAN, Gordon, James ,  SHARPE, Arlene, Helen ,  BLATTLER, Walter, A. ,  MATARAZA, Jennifer, Marie ,  SABATOS-PEYTON, Catherine, Anne ,  CHANG, Hwai, Wen ,  FREY, Gerhard, Johann

IPC分类号： A61K39/00 ,  C07K16/28 ,  A61P35/00

CPC分类号： A61K39/00 ,  A61K2039/50520130101 ,  C07K2317/2420130101 ,  C07K2317/7620130101 ,  C07K2317/9220130101 ,  C07K16/2818 ,  A61P35/00

摘要： Combination therapies comprising antibody molecules that specifically bind to PD-1 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.

公开(公告)号：EP3206711A1

公开(公告)日：2017-08-23

申请号：EP15784907.6

申请日：2015-10-13

申请人： Novartis AG ,  Dana-Farber Cancer Institute, Inc. ,  President and Fellows of Harvard College

发明人： FREEMAN, Gordon, James ,  SHARPE, Arlene, Helen ,  FREY, Gerhard, Johann ,  CHANG, Hwai, Wen ,  MATARAZA, Jennifer, Marie ,  DRANOFF, Glenn

IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K16/46

CPC分类号： C07K16/2827 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61N5/10 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57492 ,  G01N2333/70532

摘要： Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

摘要翻译： 公开了特异性结合PD-L1的抗体分子。 还公开了包含抗PD-L1抗体分子的组合疗法。 抗PD-L1抗体分子可用于治疗，预防和/或诊断癌症或感染性病症和障碍。

公开(公告)号：EP3097121A1

公开(公告)日：2016-11-30

申请号：EP15703384.6

申请日：2015-01-23

申请人： Dana-Farber Cancer Institute, Inc. ,  Novartis AG ,  President and Fellows of Harvard College

发明人： FREEMAN, Gordon, James ,  SHARPE, Arlene, Helen ,  BLATTLER, Walter, A. ,  MATARAZA, Jennifer, Marie ,  SABATOS-PEYTON, Catherine, Anne ,  CHANG, Hwai, Wen ,  FREY, Gerhard, Johann

IPC分类号： C07K16/28

CPC分类号： C07K16/2818 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/566 ,  G01N33/57484 ,  G01N33/6854 ,  G01N2333/70596 ,  Y02A50/58

摘要： Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

摘要翻译： 公开了特异性结合PD-1的抗体分子。 抗PD-1抗体分子可用于治疗，预防和/或诊断癌性或感染性疾病和病症。

公开(公告)号：EP3514179A1

公开(公告)日：2019-07-24

申请号：EP18211373.8

申请日：2015-01-23

申请人： Dana-Farber Cancer Institute, Inc. ,  Novartis AG ,  President and Fellows of Harvard College

发明人： FREEMAN, Gordon, James ,  SHARPE, Arlene, Helen ,  BLATTLER, Walter, A. ,  MATARAZA, Jennifer, Marie ,  SABATOS-PEYTON, Catherine, Anne ,  CHANG, Hwai, Wen ,  FREY, Gerhard, Johann

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61K39/395

摘要： Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

公开(公告)号：EP4378957A2

公开(公告)日：2024-06-05

申请号：EP24154217.4

申请日：2016-07-28

申请人： Novartis AG ,  Dana-Farber Cancer Institute, Inc. ,  President And Fellows Of Harvard College

发明人： DRANOFF, Glenn ,  FREEMAN, Gordon, James ,  SHARPE, Arlene, Helen ,  BLATTLER, Walter, A. ,  MATARAZA, Jennifer, Marie ,  SABATOS-PEYTON, Catherine, Anne ,  CHANG, Hwai, Wen ,  FREY, Gerhard, Johann

IPC分类号： C07K16/28

CPC分类号： A61K39/00 ,  A61K2039/50520130101 ,  C07K2317/2420130101 ,  C07K2317/7620130101 ,  C07K2317/9220130101 ,  C07K16/2818 ,  A61P35/00

摘要： Combination therapies comprising antibody molecules that specifically bind to PD-1 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.

公开(公告)号：EP4245376A2

公开(公告)日：2023-09-20

申请号：EP23169814.3

申请日：2015-10-13

申请人： Novartis AG ,  Dana-Farber Cancer Institute, Inc. ,  President and Fellows of Harvard College

发明人： FREEMAN, Gordon, James ,  SHARPE, Arlene, Helen ,  FREY, Gerhard, Johann ,  CHANG, Hwai, Wen ,  MATARAZA, Jennifer, Marie ,  DRANOFF, Glenn

IPC分类号： A61P37/02

摘要： Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

公开(公告)号：EP3328418A1

公开(公告)日：2018-06-06

申请号：EP16750330.9

申请日：2016-07-28

申请人： Novartis AG ,  Dana-Farber Cancer Institute, Inc. ,  President and Fellows of Harvard College

发明人： DRANOFF, Glenn ,  FREEMAN, Gordon, James ,  SHARPE, Arlene, Helen ,  BLATTLER, Walter, A. ,  MATARAZA, Jennifer, Marie ,  SABATOS-PEYTON, Catherine, Anne ,  CHANG, Hwai, Wen ,  FREY, Gerhard, Johann

IPC分类号： A61K39/00 ,  C07K16/28

CPC分类号： C07K16/2818 ,  A61K39/00 ,  A61K39/39541 ,  A61K2039/505 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

摘要： Combination therapies comprising antibody molecules that specifically bind to PD-1 disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.

公开(公告)号：EP3878465A1

公开(公告)日：2021-09-15

申请号：EP21152298.2

申请日：2016-07-28

申请人： Novartis AG ,  Dana-Farber Cancer Institute, Inc. ,  Children's Medical Center Corporation

发明人： DRANOFF, Glenn ,  SABATOS-PEYTON, Catherine, Anne ,  BRANNETTI, Barbara ,  HARRIS, Alan, S. ,  HUBER, Thomas ,  PIETZONKA, Thomas ,  MATARAZA, Jennifer, Marie ,  BLATTLER, Walter, A. ,  HICKLIN, Daniel, J. ,  VASQUEZ, Maximiliano ,  DEKRUYFF, Rosemarie, H. ,  UMETSU, Dale, T. ,  FREEMAN, Gordon, James ,  HU, Tiancen ,  TARASZKA, John, A. ,  XU, Fangmin

IPC分类号： A61K39/00 ,  C07K16/28 ,  A61P35/00

摘要： Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.